Paper39640496
Cytotoxic Effect of Trypanosoma cruzi Calcineurin B Against Melanoma and Adenocarcinoma Cells In Vitro.
Serrano-Rodríguez M and 3 others. Adv Pharmacol Pharm Sci, 2024. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Cytotoxic Effect of Trypanosoma cruzi Calcineurin B Against Melanoma and Adenocarcinoma Cells In Vitro. Papers, record 39640496. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39640496
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cytotoxic Effect of Trypanosoma cruzi Calcineurin B Against Melanoma and Adenocarcinoma Cells In Vitro.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11015619 | Calcineurin: form and function. | Physiol Rev | 2000 | https://conductscience.org/library/papers/11015619 | PubMed |
| 2 | 35846750 | The Kinetoplastid-Specific Protein TcCAL1 Plays Different Roles During In Vitro Differentiation and Host-Cell Invasion in Trypanosoma cruzi. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35846750 | PubMed |
| 3 | 36368477 | Cancer and Trypanosoma cruzi: Tumor induction or protection? | Biochimie | 2023 | https://conductscience.org/library/papers/36368477 | PubMed |
| 4 | 21256111 | Calcineurin B subunit interacts with proteasome subunit alpha type 7 and represses hypoxia-inducible factor-1α activity via the proteasome pathway. | Biochem Biophys Res Commun | 2011 | https://conductscience.org/library/papers/21256111 | PubMed |
| 5 | 21722668 | Calcineurin subunit B is an immunostimulatory protein and acts as a vaccine adjuvant inducing protective cellular and humoral responses against pneumococcal infection. | Immunol Lett | 2011 | https://conductscience.org/library/papers/21722668 | PubMed |
| 6 | 26519949 | Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers. | Int J Cancer | 2016 | https://conductscience.org/library/papers/26519949 | PubMed |
| 7 | 32859215 | Calcineurin. | Cell Commun Signal | 2020 | https://conductscience.org/library/papers/32859215 | PubMed |
| 8 | 33195200 | The Recombinant Protein Based on Trypanosoma cruzi P21 Interacts With CXCR4 Receptor and Abrogates the Invasive Phenotype of Human Breast Cancer Cells. | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/33195200 | PubMed |
| 9 | 27619675 | Does native Trypanosoma cruzi calreticulin mediate growth inhibition of a mammary tumor during infection? | BMC Cancer | 2016 | https://conductscience.org/library/papers/27619675 | PubMed |
| 10 | 26471241 | Calcineurin B stimulates cytokine production through a CD14-independent Toll-like receptor 4 pathway. | Immunol Cell Biol | 2016 | https://conductscience.org/library/papers/26471241 | PubMed |
| 11 | 25772545 | A novel dithiocarbamate derivative induces cell apoptosis through p53-dependent intrinsic pathway and suppresses the expression of the E6 oncogene of human papillomavirus 18 in HeLa cells. | Apoptosis | 2015 | https://conductscience.org/library/papers/25772545 | PubMed |
| 12 | 31991120 | Chapter 22: Structural and signaling functions of integrins. | Biochim Biophys Acta Biomembr | 2020 | https://conductscience.org/library/papers/31991120 | PubMed |
| 13 | 37245545 | Integrins in cancer: Emerging mechanisms and therapeutic opportunities. | Pharmacol Ther | 2023 | https://conductscience.org/library/papers/37245545 | PubMed |
| 14 | 36674930 | Toll-like Receptor 4 in Acute Kidney Injury. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36674930 | PubMed |
| 15 | 37453359 | Implications of Toll-like receptors (TLRs) and their signaling mechanisms in human cancers. | Pathol Res Pract | 2023 | https://conductscience.org/library/papers/37453359 | PubMed |
| 16 | 34631699 | Differential Expression of the TLR4 Gene in Pan-Cancer and Its Related Mechanism. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34631699 | PubMed |
| 17 | 27090571 | Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4. | Sci Rep | 2016 | https://conductscience.org/library/papers/27090571 | PubMed |
| 18 | 21447603 | Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant. | Int Immunol | 2011 | https://conductscience.org/library/papers/21447603 | PubMed |
| 19 | 32191851 | Trypanosoma cruzi Calreticulin: Immune Evasion, Infectivity, and Tumorigenesis. | Trends Parasitol | 2020 | https://conductscience.org/library/papers/32191851 | PubMed |
| 20 | 33230811 | The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target? | J Cell Physiol | 2021 | https://conductscience.org/library/papers/33230811 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41305376 | Stage-Specific Expression and Subcellular Localization of Calcineurin in Infective Forms of Leishmania amazonensis. | Pathogens | 2025 | https://conductscience.org/library/papers/41305376 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39640496
GET https://conductscience.org/api/papers/v1/39640496/references?page=2